Daily non-political popular news in brief.

Skin rash actually signifies better outcomes for pancreatic and lung cancer patients

The appearance of a rash in cancer patients treated with erlotinib (Tarceva) is strongly associated with longer survival, according to researchers from the drug’s developer, OSI Pharmaceuticals, Inc. This is not the first time that rash has been associated with a survival advantage with EGFR inhibitors -- a class of drugs which includes erlotinib, cetuximab, panitumumab and others designed to block overproduction of the epidermal growth factor receptor -- but it is the most detailed analysis to date.

Read more »

Keywords: skin, rash, actually, signifies, outcomes, pancreatic, lung, cancer, patients, signify, outcome, patient

« Previous | Next »

Similar news on "Skin rash actually signifies better outcomes for pancreatic and lung cancer patients":

1. Gene signature spells poor outcome
   08-30-2007 · EurekAlert!
   Other than visually inspecting the disease, doctors have no genetic blueprint to classify melanomas, a lethal form of skin cancer. Tumors generally are ranked by how deeply the growth has invaded underlying skin tissue. The deeper it burrows into the skin, the more lethal the cancer, but some patients defy the odds and survive with thick tumors or die from thin ones.
   Similar news · Read more »
   
2. Minimally invasive lung cancer surgery can improve chemotherapy outcomes
   04-09-2007 · EurekAlert!
   Patients who undergo a minimally invasive lung cancer surgery called thoracoscopic lobectomy may derive more benefit from the chemotherapy that follows, according to Duke University Medical Center researchers. These patients also have shorter hospital stays and accelerated recovery time compared with patients who have their tumors removed using the traditional surgical approach that involves opening the chest.
   Similar news · Read more »
   
3. Pancreatic cancer vaccine halts progression of disease in some patients
   04-17-2007 · EurekAlert!
   A dendritic cell-based therapeutic vaccine for pancreatic cancer developed by researchers at the University of Pittsburgh School of Medicine has successfully stalled the disease from progressing in a handful of patients three years post-vaccination. The results, part of a press briefing on cancer vaccines held at the annual meeting of the American Association of Cancer Research, provide promising evidence that the vaccine can trigger a patient's own immune system to rally against pancreatic cancer.
   Similar news · Read more »
   
4. Pre-treatment blood test could guide lung cancer therapy
   06-05-2007 · EurekAlert!
   A multi-center team, led by Vanderbilt-Ingram Cancer Center investigators, has developed a new pre-treatment blood test that predicts which non-small-cell lung cancer patients will live longer when they are treated with certain targeted cancer therapies (Iressa, Tarceva). The mass spectrometry-based test, described in the June 6 Journal of the National Cancer Institute, may allow physicians to select the most beneficial therapy for each lung cancer patient, a step forward in the era of personalized medicine.
   Similar news · Read more »
   
5. Research shows cord blood comparable to matched bone marrow
   06-07-2007 · EurekAlert!
   University of Minnesota researchers report that umbilical cord blood transplants may offer blood cancer patients better outcomes than bone marrow transplants, according to an analysis of outcome data performed at the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee.
   Similar news · Read more »
   
6. New algorithms classify outcomes of nonsmall cell lung cancer patients
   06-05-2007 · EurekAlert!
   Two research teams have developed models for classifying the clinical outcomes of patients with nonsmall cell lung cancer using mass spectrometry techniques. The studies are published in the June 6 Journal of the National Cancer Institute.
   Similar news · Read more »
   
7. Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer
   09-25-2007 · EurekAlert!
   Researchers have found that the breast cancer susceptibility gene, BRCA1, plays a significant role in nonsmall cell lung cancer. They told the European Cancer Conference in Barcelona that not only can it be used to predict outcome for patients with NSCLC, but it may also prove to be a valuable tool in choosing the best therapy for them.
   Similar news · Read more »
   
8. Patient navigators help minority, low-income cancer patients get life-saving treatments
   10-28-2007 · EurekAlert!
   Volunteers who guide low-income and minority cancer patients through cancer treatment, called lay patient navigators, help them to overcome major obstacles that prevent them from receiving quality care and achieving better outcomes, according to a study presented Oct. 28, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.
   Similar news · Read more »
   
9. Mouse Tests Predict Drug Response In Relapsing Pancreatic Cancer Patients
   10-12-2006 · ScienceDaily
   By slicing up bits of patient tumors and grafting them into mice, Johns Hopkins Kimmel Cancer Center specialists have figured out how to accurately 'test drive' chemotherapy drugs to learn in advance which drug treatments offer each individual pancreatic cancer patient the best therapeutic journey.
   Similar news · Read more »
   
10. Studies suggest key correlation between lung cancer subtype and treatment outcomes
    09-26-2007 · EurekAlert!
    In clinical research, patients with advanced non-small cell lung cancer that are classified as having a non-squamous histology achieve statistically significant higher survival when treated in the second-line setting with ALIMTA (pemetrexed for injection) when compared to histologically-similar patients treated with docetaxel.
    Similar news · Read more »